BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 234 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $2,267,000 | -75.0% | 660,000 | -65.3% | 0.62% | -76.5% |
Q2 2020 | $9,054,000 | +1710.8% | 1,900,000 | +660.0% | 2.62% | +981.0% |
Q1 2020 | $500,000 | -94.9% | 250,000 | -91.2% | 0.24% | -90.0% |
Q4 2019 | $9,746,000 | +4677.5% | 2,825,000 | +11200.0% | 2.41% | +2388.7% |
Q1 2019 | $204,000 | +1.0% | 25,000 | 0.0% | 0.10% | -37.0% |
Q4 2018 | $202,000 | -95.4% | 25,000 | -97.2% | 0.15% | -81.5% |
Q4 2017 | $4,419,000 | -15.4% | 900,000 | -9.7% | 0.83% | -10.9% |
Q3 2017 | $5,221,000 | +456.6% | 996,300 | +490.6% | 0.94% | +255.9% |
Q2 2017 | $938,000 | -91.0% | 168,685 | -86.5% | 0.26% | -89.4% |
Q1 2017 | $10,461,000 | +563.3% | 1,245,310 | +400.1% | 2.48% | +323.2% |
Q4 2016 | $1,577,000 | -49.8% | 249,000 | -65.0% | 0.59% | -50.3% |
Q3 2016 | $3,141,000 | +1.5% | 712,248 | +162.4% | 1.18% | -34.1% |
Q3 2015 | $3,094,000 | – | 271,399 | – | 1.79% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |